Chen F, Wang L W, Bu J Q
Department of Stomatology,the First Medical Centre of Chinese PLA General Hospital, Beijing 100853, China.
Zhonghua Yi Xue Za Zhi. 2022 May 17;102(18):1394-1397. doi: 10.3760/cma.j.cn112137-20211111-02515.
The clinical data of 61 patients of salivary duct carcinoma admitted to the First Medical Centre of Chinese PLA General Hospital from January 2010 to December 2020 were retrospectively reviewed. A total of 55 patients (90.2%) were male and 6 (9.8%) were female. There were 51 patients (83.6%) aged≥50 years. The primary tumor of 45 patients (73.8%) were from the parotid gland. There were 35 patients (57.4%) who had cervical lymph node metastasis and 25 patients (41.0%) had distant metastasis. All patients underwent surgery and 50 of them (82.0%) received adjuvant radiotherapy. The 3-year and 5-year survival rates were 58.0% and 43.3%, respectively. Compared with the patients who had undergone surgery only, the survival rates of those who had postoperative adjuvant radiotherapy and chemoradiotherapy were higher. It can be seen that radical surgical treatment is necessary, and postoperative radiotherapy can reduce the recurrence rate and increase the survival rate to a certain extent.
回顾性分析2010年1月至2020年12月解放军总医院第一医学中心收治的61例涎腺导管癌患者的临床资料。55例（90.2%）为男性，6例（9.8%）为女性。51例（83.6%）患者年龄≥50岁。45例（73.8%）患者的原发肿瘤位于腮腺。35例（57.4%）患者发生颈部淋巴结转移，25例（41.0%）患者发生远处转移。所有患者均接受手术治疗，其中50例（82.0%）接受辅助放疗。3年和5年生存率分别为58.0%和43.3%。与仅接受手术治疗的患者相比，接受术后辅助放疗和放化疗的患者生存率更高。可见根治性手术治疗是必要的，术后放疗可在一定程度上降低复发率、提高生存率。
